

DAFTAR PUSTAKA

- Achmad Rudijanto, Agus Yuwono, Alwi Shahab, Asman Manaf, Bowo Pramono, D.L., *et al.*, 2015. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015, *Perkeni*.
- Alves-Filho, J.C., Sônego, F., Souto, F.O., Freitas, A., Verri, W.A., Auxiliadora-Martins, *et al.*, 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. *Nat. Med.* 16, 708–712.
- Ardhana, T., Aminuddin, M., Nugraha, J., 2013. Relationship between NT-proBNP Level and Protein ST2 Level. *Fol. Med. Ind.* 49, 202-207.
- Barbarash, O., Gruzdeva, O., Uchasova, E., Dyleva, Y., Belik, E., Akbasheva, O., *et al.*, 2016. Prognostic value of soluble ST2 during hospitalization for st-segment elevation myocardial infarction. *Ann. Lab. Med.* 36, 313–319.
- Bayés-Genís, A., Núñez, J., Lupón, J., 2017. Soluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard? *J. Am. Coll. Cardiol.* 70, 2389–2392.
- Brunner, M., Krenn, C., Roth, G., Moser, B., Dworschak, M., Jensen-Jarolim, E., *et al.*, 2004. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. *Intensive Care Med.* 30, 1468–73.
- Carbone, F., Nencioni, A., Mach, F., Vuilleumier, N., Montecucco, F., 2013. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. *Thromb. Haemost.* 109, 854–868.
- Celic, V., Majstorovic, A., Pencic-Popovic, B., Sljivic, A., Lopez-Andres, N., Roy, I., Escribano, E., *et al.*, 2016. Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome. *Ann. Lab. Med.* 36, 542–9.
- Chia, S., Nagurney, J.T., Brown, D.F.M., Raffel, O.C., Bamberg, F., Senatore, F., 2009. Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. *Am. J. Cardiol.* 103, 333–337.
- Demyanets, S., Speidl, W.S., Tentzeris, I., Jarai, R., Katsaros, K.M., Farhan, S., *et al.*, 2014. Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome. *PLoS One* 9, e95055.
- Departemen Kesehatan Republik Indonesia. (2013). Riset Kesehatan Dasar 2013. Status Gizi Penduduk Dewasa. *Depkes RI*.

- Espinassous, Q., Garcia-de-Paco, E., Garcia-Verdugo, I., Synguelakis, M., von Aulock, S., *et al.*, 2009. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. *J. Immunol.* 183, 1446–55.
- Ferrari, J.P., Lueneberg, M.E., da Silva, R.L., Fattah, T., Gottschall, C.A.M., Moreira, D.M., 2016. Correlation between leukocyte count and infarct size in ST segment elevation myocardial infarction. *Arch. Med. Sci. Atheroscler. Dis.* 1, e44–e48.
- Fu, W.-X., Zhou, T.-N., Wang, X.-Z., Zhang, L., Jing, Q.-M., Han, Y.-L., 2018. Sex-Related Differences in Short- and Long-Term Outcome among Young and Middle-Aged Patients for ST-Segment Elevation Myocardial Infarction Underwent Percutaneous Coronary Intervention. *Chin. Med. J. (Engl.)*. 131, 1420–1429.
- Hartopo, A. B., Setianto, B. Y., Taufiq, N., 2016. Pengaruh kadar soluble ST2 serum terhadap risiko kejadian kardiovaskular mayor selama perawatan intensif pada infark miokard akut dengan elevasi segmen-ST. *Tesis.* Fakultas Kedokteran Universitas Gadjah Mada, Program Pendidikan Dokter Spesialis Ilmu Penyakit Jantung dan Pembuluh Darah.
- Hartopo, A.B., Sukmasari, I., Puspitawati, I., 2018. The Utility of Point of Care Test for Soluble ST2 in Predicting Adverse Cardiac Events during Acute Care of ST-Segment Elevation Myocardial Infarction. *Cardiol. Res. Pract.* 2018, 3048941
- Hesse, B., Lindhardt, T.B., Acampa, W., Anagnostopoulos, C., Ballinger, J., Bax, J.J., Edenbrandt, *et al.*, 2008. EANM/ESC guidelines for radionuclide imaging of cardiac function.
- Huang, W.P., Zheng, X., He, L., Su, X., Liu, C.W., Wu, M.X., 2018. Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction. *Chin. Med. J. (Engl.)*. 131, 1282–1288.
- Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.P., *et al.*, 2018. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* 39, 119–177.
- Iikura, M., Suto, H., Kajiwara, N., Oboki, K., Ohno, T., Okayama, Y., Saito, H., 2007. IL-33 can promote survival, adhesion and cytokine production in human mast cells. *Lab. Investig.* 87, 971–978.
- James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., *et al.*, 2014. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. *JAMA* 311, 507.

- Jensen, M.T., Pereira, M., Araujo, C., Malmivaara, A., Ferrieres, J., Degano, I.R., *et al.*, 2018. Heart rate at admission is a predictor of in-hospital mortality in patients with acute coronary syndromes: Results from 58 European hospitals: The European Hospital Benchmarking by Outcomes in acute coronary syndrome Processes study. *Eur. Hear. J. Acute Cardiovasc. Care* 7, 149–157.
- Jernberg, T., Johanson, P., Held, C., Svennblad, B., Lindbäck, J., Wallentin, L., SWEDEHEART/RIKS-HIA, 2011. Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction. *JAMA* 305, 1677.
- Killip, T., Kimball, J.T., 1967. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. *Am. J. Cardiol.* 20, 457–64.
- Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R.C., Stolarski, B., Garcia, C.C., *et al.*, 2008. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. *J. Immunol.* 181, 4780–90.
- Lee, C.T., Williams, G.H., Lilly, L.S., 2011. Pathophysiology of Heart Disease 5th Edition.
- Libby, P., Tabas, I., Fredman, G., Fisher, E.A., 2014. Inflammation and its Resolution as Determinants of Acute Coronary Syndromes. *Circ. Res.* 114, 1867–1879.
- Massalha, S., Luria, L., Kerner, A., Roguin, A., Abergel, E., Hammerman, H., *et al.*, 2016. Heart failure in patients with diabetes undergoing primary percutaneous coronary intervention. *Eur. Hear. J. Acute Cardiovasc. Care* 5, 455–462.
- Miller, A.M., Liew, F.Y., 2011. The IL-33/ST2 pathway — A new therapeutic target in cardiovascular disease. *Pharmacol. Ther.* 131, 179–186.
- Miñana, G., Núñez, J., Bayés-Genís, A., Revuelta-López, E., Ríos-Navarro, C., Núñez, E., *et al.*, 2018. ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. *Int. J. Cardiol.*
- Mistry, N., Halvorsen, S., Hoffmann, P., Müller, C., Böhmer, E., Kjeldsen, S.E., *et al.*, 2010. Assessment of left ventricular function with magnetic resonance imaging vs. echocardiography, contrast echocardiography, and single-photon emission computed tomography in patients with recent ST-elevation myocardial infarction. *Eur. Hear. J. - Cardiovasc. Imaging* 11, 793–800.
- Montecucco, F., Carbone, F., Schindler, T.H., 2016. Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments.

Eur. Heart J. 37, 1268–1283.

Montecucco, F., Vuilleumier, N., Pagano, S., Lenglet, S., Bertolotto, M., Braunersreuther, *et al.*, 2011. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. *Eur. Heart J.* 32, 412–421.

Moore, K. L., Dalley, A. F., Agur, A.M.R., 2010. Clinically Oriented Anatomy 6th ed.

Ndrepepa, G., Mehilli, J., Martinoff, S., Schwaiger, M., Schömig, A., Kastrati, A., 2007. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. *J. Am. Coll. Cardiol.* 50, 149–56.

Nugroho, D.T.W., Aminuddin, M., Nugraha, J., 2014. Correlation between serum level of heart type fatty acid binding protein (HFABP) and soluble ST2 in acute coronary syndrome patient. *Eur. J. Heart Fail.* 16, 9.

O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., de Lemos, J.A., *et al.*, 2013. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 127, e362–e425.

Sabatine, M.S., Morrow, D.A., Higgins, L.J., MacGillivray, C., Guo, W., Bode, C., *et al.*, 2008. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. *Circulation* 117, 1936–1944.

Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., *et al.*, 2005. IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. *Immunity* 23, 479–490.

Shah, A.M., Pfeffer, M.A., Hartley, L.H., Moyé, L.A., Gersh, B.J., Rutherford, J.D., *et al.*, 2010. Risk of All-Cause Mortality, Recurrent Myocardial Infarction, and Heart Failure Hospitalization Associated With Smoking Status Following Myocardial Infarction With Left Ventricular Dysfunction. *Am. J. Cardiol.* 106, 911–916.

Shimpo, M., Morrow, D.A., Weinberg, E.O., Sabatine, M.S., Murphy, S.A., Antman, E.M., *et al.*, 2004. Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction. *Circulation* 109, 2186–2190.

Shirakabe, A., Hata, N., Kobayashi, N., Okazaki, H., Matsushita, M., Shibata, Y., *et al.*, 2018. Decreased blood glucose at admission has a prognostic impact in patients with severely decompensated acute heart failure complicated

with diabetes mellitus. *Heart Vessels* 33, 1008–1021.

Solomon, S.D., Glynn, R.J., Greaves, S., Ajani, U., Rouleau, J.L., Menapace, F., *et al.*, 2001. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. *Ann. Intern. Med.* 134, 451–8.

Steg, P.G., Dabbous, O.H., Feldman, L.J., Cohen-Solal, A., Aumont, M.-C., López-Sendón, J., *et al.*, 2004. Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes Observations From the Global Registry of Acute Coronary Events (GRACE). *Circulation* 109, 494–499.

Steg, P.G., James, S.K., Atar, D., Badano, L.P., Lundqvist, C.B., Borger, M.A., *et al.*, 2012. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* 33, 2569–2619.

Tago, K., Noda, T., Hayakawa, M., Iwahana, H., Yanagisawa, K., Yashiro, T., 2001. Tissue Distribution and Subcellular Localization of a Variant Form of the Human ST2 Gene Product, ST2V. *Biochem. Biophys. Res. Commun.* 285, 1377–1383.

Thygesen, K., Alpert, J.S., Jaffe, A.S., Chaitman, B.R., Bax, J.J., Morrow, D.A., White, H.D., 2018. Fourth Universal Definition of Myocardial Infarction (2018). *J. Am. Coll. Cardiol.*

Tominaga, S. ichi, 1989. A putative protein of a growth specific cDNA from BALB/C-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. *FEBS Lett.* 258, 301–304.

Townsend, M.J., Fallon, P.G., Matthews, D.J., Jolin, H.E., McKenzie, A.N., 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. *J. Exp. Med.* 191, 1069–76.

Verri, W.A., Souto, F.O., Vieira, S.M., Almeida, S.C.L., Fukada, S.Y., Xu, D., *et al.*, 2010. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. *Ann. Rheum. Dis.* 69, 1697–703.

Vicent, L., Velásquez-Rodríguez, J., Valero-Masa, M.J., Díez-Delhoyo, F., González-Saldívar, H., Bruña, V., *et al.*, 2017. Predictors of high Killip class after ST segment elevation myocardial infarction in the era of primary reperfusion. *Int. J. Cardiol.* 248, 46–50.

Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., MacGillivray, C., Tominaga, S., Solomon, S.D., *et al.*, 2002. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. *Circulation* 106, 2961–6.

Weir, R.A.P., Miller, A.M., Murphy, G.E.J., Clements, S., Steedman, T., Connell, J.M.C., *et al.*, 2010. Serum Soluble ST2 A Potential Novel Mediator in Left Ventricular and Infarct Remodeling After Acute Myocardial Infarction. *J. Am. Coll. Cardiol.* 55, 243–50.